Titan Pharmaceuticals Stock Performance
| TTNP Stock | USD 4.19 0.54 14.79% |
On a scale of 0 to 100, Titan Pharmaceuticals holds a performance score of 6. The entity has a beta of -0.28, which indicates not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Titan Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Titan Pharmaceuticals is likely to outperform the market. Please check Titan Pharmaceuticals' semi variance, as well as the relationship between the rate of daily change and relative strength index , to make a quick decision on whether Titan Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Titan Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Even with relatively inconsistent basic indicators, Titan Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 6.8 M | |
| Free Cash Flow | -3.9 M |
Titan |
Titan Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 347.00 in Titan Pharmaceuticals on December 24, 2024 and sell it today you would earn a total of 72.00 from holding Titan Pharmaceuticals or generate 20.75% return on investment over 90 days. Titan Pharmaceuticals is currently generating 0.4746% in daily expected returns and assumes 5.8568% risk (volatility on return distribution) over the 90 days horizon. In different words, 52% of stocks are less volatile than Titan, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Titan Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Titan Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Titan Pharmaceuticals, and traders can use it to determine the average amount a Titan Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.081
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | TTNP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.86 actual daily | 52 52% of assets are less volatile |
Expected Return
| 0.47 actual daily | 9 91% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Titan Pharmaceuticals is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Titan Pharmaceuticals by adding it to a well-diversified portfolio.
Titan Pharmaceuticals Fundamentals Growth
Titan Stock prices reflect investors' perceptions of the future prospects and financial health of Titan Pharmaceuticals, and Titan Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Titan Stock performance.
| Return On Equity | -3.69 | ||||
| Return On Asset | -1.73 | ||||
| Current Valuation | (2.42 M) | ||||
| Shares Outstanding | 914.23 K | ||||
| Price To Earning | (3.60) X | ||||
| Price To Book | 1.52 X | ||||
| Price To Sales | 1,234 X | ||||
| Revenue | 3 K | ||||
| EBITDA | (4.56 M) | ||||
| Cash And Equivalents | 6.42 M | ||||
| Cash Per Share | 0.44 X | ||||
| Total Debt | 483 K | ||||
| Debt To Equity | 0.04 % | ||||
| Book Value Per Share | 4.37 X | ||||
| Cash Flow From Operations | (3.88 M) | ||||
| Earnings Per Share | (6.64) X | ||||
| Total Asset | 2.92 M | ||||
| Retained Earnings | (396.54 M) | ||||
| Current Asset | 12.24 M | ||||
| Current Liabilities | 4.85 M | ||||
About Titan Pharmaceuticals Performance
Assessing Titan Pharmaceuticals' fundamental ratios provides investors with valuable insights into Titan Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Titan Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. The company was incorporated in 1992 and is based in South San Francisco, California. Titan Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.Things to note about Titan Pharmaceuticals performance evaluation
Checking the ongoing alerts about Titan Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Titan Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Titan Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 3 K. Net Loss for the year was (4.71 M) with loss before overhead, payroll, taxes, and interest of (4.37 M). | |
| Titan Pharmaceuticals currently holds about 6.42 M in cash with (3.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44. | |
| Roughly 45.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Titan Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Titan Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Titan Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Titan Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Titan Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Titan Pharmaceuticals' stock. These opinions can provide insight into Titan Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Titan Stock Analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.